Answers are grounded in this paper and cite their sources.
Blocking PD-1/PD-L1 interaction shows remarkable antitumor efficacy clinically but systemic administration can cause immune-related adverse events in multiple organs from nonspecific T-cell activation, restricting the clinical safety window. Achieving spatiotemporal regulation of immune checkpoint blockadepreserving antitumor immunity while avoiding systemic toxicityis a key challenge. Prodrug strategies, particularly photocaging, enable on-demand light-triggered drug activation. Here, we propose a prodrug design for small-molecule PD-L1 inhibitors using coumarin photocaging groups. Guided by cocrystal binding mode analysis, we covalently masked two inhibitors with coumarin photolabile protecting groups, and designed and synthesized the corresponding photocaged prodrugs. In vitro, the prodrugs were inactive under dark conditions, but upon visible light activation, they restored T-cell effector function and restored T-cell effector function in PD-L1-dependent co-culture models. These results validate the on-demand release pharmacological property, providing a feasible approach for spatiotemporally controllable immunotherapy in superficial or optically accessible lesions.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: